We are monitoring the impact of COVID-19 on Latin America Migraine Drug Market Get in touch with us for detailed analysis Know More
Share on

Latin America Migraine Drug Market Research Report - Segmented By Treatment, Therapeutic Class & Country (Mexico, Brazil, Argentina, Chile and Rest of Latin America)- Industry Analysis, Size, Share, Trends & Growth Forecast (2022 to 2027)

Published: January, 2022
ID: 3954
Pages: 145

Latin America Migraine Drug Market Size (2022 to 2027)

As per the research report, the size of the Latin American Migraine Drug Market has been calculated at USD 0.57 billion in 2022. It is further estimated to be growing at a CAGR of 4.98% and worth USD 0.72 billion by 2027.

Migraines are becoming increasingly common in the rising female population. Hormonal changes in women are one of the migraine triggers. Hormone fluctuations, such as before or during menstrual cycles, pregnancy, and menopause, appear to cause headaches in many women. In addition, hormonal drugs, such as oral contraceptives, might also aggravate migraines.

Migraine is typically diagnosed by reviewing the patient's medical history and symptoms and performing blood tests, magnetic resonance imaging (MRI), and computed tomography (CT) scans. In addition, over-the-counter (OTC) medications and prescription injections are currently available to ease symptoms and reduce the frequency and intensity of migraine attacks. These medications are taken regularly or only when there is a flare-up or exacerbation of chronic pain.

The prevalence of migraine is significantly growing in Latin American countries, which is primarily expected to accelerate the growth rate of the migraine drugs market in the Latin American region. Also, increasing awareness among the patients about the prevention and treatment of migraine and the rising demand for precision medicines are fuelling the market growth. On the other hand, rising demand for electrical nerve stimulation devices to treat migraines, as well as the expected approval of new classes of drugs with higher clinical efficacy in the late-stage pipeline, such as the introduction of calcitonin gene-related peptide (CGRP) monoclonal antibodies, are propelling the market growth.

Other factors such as increasing alcohol consumption, work pressure, growing population, and rising demand for quality drugs influence market growth. Increasing investment and funding by the government and key market players in research and development activities and migraine drug development is expected to provide lucrative growth opportunities for the market growth. 

However, side effects associated with migraine usage are expected to restrain the growth of the Latin American migraine drugs market. In addition, stringent regulations by the government on migraine drugs and the availability of alternative therapies are further limit the market growth. Furthermore, a lack of awareness regarding the proper treatment is expected to restrict the market growth.

This research report on the Latin American migraine drugs market has been segmented and sub-segmented into the following categories:

By Treatment: 

  • Preventive
  • Absorptive

By Therapeutic Class: 

  • Triptants
  • Ergots
  • Others

By Country: 

  • Mexico
  • Brazil
  • Argentina
  • Chile
  • Rest of Latin America

Geographically, Latin America is projected to grow significantly during the forecast period. The factors such as improvements in the healthcare sector, increasing demand for better healthcare services, and favorable reimbursement policies are expected to fuel the market growth. In addition, emerging countries such as Argentina, Brazil, and Mexico are contributing to the regional market growth with a significant market share. 

Brazil held the largest market share in 2020, and it is anticipated to register a prominent share during the forecast period. The increasing migraine, high research, and development activities, and growing healthcare expenditure are expected to fuel the market growth. 

Mexico is anticipated to witness a significant share in the market during the forecast period. The factors such as the growing population, increasing adoption of sedentary lifestyles, and the high prevalence of neurological disorders are boosting the market growth. 

On the other hand, Argentina is one of the fastest-growing countries in Latin America. The growing female population, rising awareness, growing demand for better healthcare facilities, and supportive government policies promote the market growth. 

KEY MARKET PLAYERS:

Companies playing a leading role in the Latin American migraine drug market profiled in the report are Allergan, GlaxoSmithKline, Pfizer, Endo, Impax Laboratories. The other prominent vendors in the market include AbbottAeriel BioPharma, Alder Biopharmaceuticals, Amgen, Astellas, Bayer, CoLucid, Eli Lilly, IntelGenx, Ethypharm, Johnson & Johnson, Kowa Pharmaceuticals America, Klaria, Luitpold Pharmaceuticals, AstraZeneca, Meda, Dr. Reddy's Laboratories, OptiNose, Pfizer, Pozen, Eisai, Raptor, RedHill, SUDA, Teva, Aegis Therapeutics, Merck, TG Therapeutics, NValeant, Winston Pharmaceuticals, Allergan, and Zogenix.

1.Introduction                                  

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods   

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                               

                2.2 Research Phases                      

                                2.2.1 Secondary Research           

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling      

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                       

                3.1 Executive Summary                

                3.2 Key Inferences                         

                3.3 Epidemology                              

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                    

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market                              

5. Market Segmentation                                              

                5.1 Treatment                  

                                5.1.1 Introduction           

                                5.1.2 Preventive              

                                5.1.3 Abortive   

                                5.1.4  Y-o-Y Growth Analysis, By Treatment         

                                5.1.5  Market Attractiveness Analysis, By Treatment       

                                5.1.6  Market Share Analysis, By Treatment        

                5.2 Therapeutic                

                                5.2.1 Introduction           

                                5.2.2 Triptents  

                                5.2.3 Ergots        

                                5.2.4 Others      

                                5.2.5 Y-o-Y Growth Analysis, By Therapeutic       

                                5.2.6 Market Attractiveness Analysis, By Therapeutic     

                                5.2.7 Market Share Analysis, By Therapeutic       

6. Geographical Analysis                                              

                6.1 Introduction                               

                                6.1.1 Regional Trends    

                                6.1.2 Impact Analysis     

                                6.1.3 Y-o-Y Growth Analysis        

                                                6.1.3.1 By Geographical Area

                                                6.1.3.2 By Treatment

                                                6.1.3.3 By Therapeutic

                                6.1.4  Market Attractiveness Analysis     

                                                6.1.4.1 By Geographical Area

                                                6.1.4.2 By Treatment

                                                6.1.4.3 By Therapeutic

                                6.1.5  Market Share Analysis      

                                                6.1.5.1 By Geographical Area

                                                6.1.5.2 By Treatment

                                                6.1.5.3 By Therapeutic

                6.2 Brazil                             

                6.3 Mexico                         

                6.4 Rest of Latin America                             

7.Strategic Analysis                                        

                7.1 PESTLE analysis                         

                                7.1.1 Political     

                                7.1.2 Economic 

                                7.1.3 Social         

                                7.1.4 Technological         

                                7.1.5 Legal          

                                7.1.6 Environmental       

                7.2 Porter’s Five analysis                              

                                7.2.1 Bargaining Power of Suppliers        

                                7.2.2 Bargaining Power of Consumers    

                                7.2.3 Threat of New Entrants     

                                7.2.4 Threat of Substitute Products and Services              

                                7.2.5 Competitive Rivalry within the Industry     

8.Market Leaders' Analysis                                         

                8.1 Allergan                       

                                8.1.1 Overview 

                                8.1.2 Product Analysis   

                                8.1.3 Financial analysis  

                                8.1.4 Recent Developments       

                                8.1.5 SWOT analysis       

                                8.1.6 Analyst View          

                8.2 Endo International                  

                8.3  GlaxoSmithKline                      

                8.4 Impax                           

                8.5 Pfizer                            

                8.6 Aegis Therapeutics                  

                8.7 Alder Biopharmaceuticals                     

                8.8 Astellas                        

                8.9 AstraZeneca                               

                8.10 Aeriel BioPharma                   

9.Competitive Landscape                                            

                9.1 Market share analysis                            

                9.2 Merger and Acquisition Analysis                       

                9.3 Agreements, collaborations and Joint Ventures                         

                9.4 New Product Launches                         

10.Market Outlook and Investment Opportunities                                          

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  1. Latin America Migraine Drug Market, By Treatment, From 2022 - 2027 (USD  Billion)
  2. Latin America Preventive Market, By Region, From 2022 - 2027 (USD  Billion)
  3. Latin America abortive Market, By Region, From 2022 - 2027 (USD  Billion)
  4. Latin America Migraine Drug Market, By Therapeutic, From 2022 - 2027 (USD  Billion)
  5. Latin America Triptents Market, By Region, From 2022 - 2027 (USD  Billion)
  6. Latin America Ergots Market, By Region, From 2022 - 2027 (USD  Billion)
  7. Latin America Others Market, By Region, From 2022 - 2027 (USD  Billion)
  8. Brazil Migraine Drug Market, By Treatment, From 2022 - 2027 (USD  Billion)
  9. Brazil Migraine Drug Market, By Therapeutic, From 2022 - 2027 (USD  Billion)
  10. Argentina Migraine Drug Market, By Treatment, From 2022 - 2027 (USD  Billion)
  11. Argentina Migraine Drug Market, By Therapeutic, From 2022 - 2027 (USD  Billion)
  12. Mexico Migraine Drug Market, By Treatment, From 2022 - 2027 (USD  Billion)
  13. Mexico Migraine Drug Market, By Therapeutic, From 2022 - 2027 (USD  Billion)
  14. Rest of Latin America Migraine Drug Market, By Treatment, From 2022 - 2027 (USD  Billion)
  15. Rest of Latin America Migraine Drug Market, By Therapeutic, From 2022 - 2027 (USD  Billion)

Please wait. . . . Your request is being processed

Related Reports

PURCHASE OPTIONS

excel
$

2875


pdf excel
$

3220


pdf excel powerbi
$

4600


excel
$

2000

What You Get :

  • PDF Report Format.
  • Can be accessible by 1 single user.
  • 6 Months of Free Analyst Support.
  • PDF and Excel Datasheet Formats.
  • Can be accessible upto 2 to 5 users.
  • 1 Year of Free Analyst Support.
  • PDF, Excel and Power BI Dashboard.
  • Can be accessible by unlimited users.
  • 1 Year of Free Analyst Support.
  • Excel Datasheet Format.
  • Customized access as per user request.
  • Upgradable to other licenses.
customer-support
ASK FOR CUSTOMIZATION

Talk to our analyst and get customised report done according to your research needs

tag
INQUIRE FOR DISCOUNT

Check if you can avail any discount. Submit your details and our team will get back to you.

cloud-download
DOWNLOAD FREE SAMPLE

Request to avail a free sample report that reflects this market and its growth.

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2875

Didn’t find what you’re looking for?
TALK TO OUR TEAM

Find it too expensive?
NO WORRIES!

Click for Request Sample